Form 8-K - Current report:
SEC Accession No. 0000950170-24-121069
Filing Date
2024-11-05
Accepted
2024-11-05 07:05:17
Documents
13
Period of Report
2024-11-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K beam-20241105.htm   iXBRL 8-K 48746
2 EX-99.1 beam-ex99_1.htm EX-99.1 141099
3 GRAPHIC img55885398_0.jpg GRAPHIC 12215
  Complete submission text file 0000950170-24-121069.txt   334869

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT beam-20241105.xsd EX-101.SCH 29593
15 EXTRACTED XBRL INSTANCE DOCUMENT beam-20241105_htm.xml XML 4518
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 857-327-8775
Beam Therapeutics Inc. (Filer) CIK: 0001745999 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39208 | Film No.: 241425595
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)